CryoPort (NASDAQ:CYRX) CEO Sells $63,344.00 in Stock
by Renee Jackson · The Cerbat GemCryoPort, Inc. (NASDAQ:CYRX – Get Free Report) CEO Jerrell Shelton sold 7,918 shares of the stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $8.00, for a total transaction of $63,344.00. Following the transaction, the chief executive officer directly owned 1,054,501 shares in the company, valued at approximately $8,436,008. This represents a 0.75% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
CryoPort Stock Up 4.5%
Shares of NASDAQ CYRX traded up $0.36 during trading on Tuesday, hitting $8.36. 401,705 shares of the company traded hands, compared to its average volume of 429,763. The firm has a market capitalization of $416.83 million, a P/E ratio of 6.33 and a beta of 1.69. The company has a 50-day moving average price of $9.19 and a 200-day moving average price of $9.36. CryoPort, Inc. has a 1 year low of $4.63 and a 1 year high of $11.45.
CryoPort (NASDAQ:CYRX – Get Free Report) last issued its earnings results on Tuesday, March 3rd. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.02). CryoPort had a negative return on equity of 8.22% and a net margin of 42.35%.The firm had revenue of $45.45 million during the quarter, compared to analysts’ expectations of $42.92 million. Research analysts predict that CryoPort, Inc. will post -0.99 EPS for the current fiscal year.
Analyst Ratings Changes
A number of equities analysts have recently commented on CYRX shares. Weiss Ratings restated a “sell (d+)” rating on shares of CryoPort in a report on Monday, December 29th. Needham & Company LLC boosted their target price on CryoPort from $12.00 to $13.00 and gave the stock a “buy” rating in a report on Wednesday, March 4th. Finally, Wall Street Zen lowered shares of CryoPort from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. Eight analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $12.94.
Read Our Latest Stock Report on CryoPort
Institutional Trading of CryoPort
Several large investors have recently added to or reduced their stakes in the stock. Basepoint Wealth LLC purchased a new position in CryoPort in the fourth quarter valued at about $34,000. Tower Research Capital LLC TRC boosted its position in shares of CryoPort by 300.1% in the second quarter. Tower Research Capital LLC TRC now owns 5,833 shares of the company’s stock worth $44,000 after buying an additional 4,375 shares during the period. Whittier Trust Co. of Nevada Inc. acquired a new stake in shares of CryoPort in the third quarter valued at about $53,000. ProShare Advisors LLC acquired a new stake in shares of CryoPort in the second quarter valued at about $75,000. Finally, AlphaQuest LLC purchased a new stake in shares of CryoPort during the 3rd quarter valued at about $79,000. 92.90% of the stock is currently owned by institutional investors and hedge funds.
CryoPort Company Profile
CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.
CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.